The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - MSD; Ono Pharmaceutical
Research Funding - Bristol-Myers Squibb (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Honoraria - Bristol-Myers Squibb Japan; MSD; Novartis; Ono Pharmaceutical
Consulting or Advisory Role - Novartis
Real-world efficacy of anti-PD-1 antibodies in advanced acral melanoma patients: A retrospective, multicenter study (JAMP study).
 
Yasuhiro Nakamura
Honoraria - Bristol-Myers Squibb Japan; Maruho; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Taisho Toyama Pharma
Consulting or Advisory Role - MSD; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Kenjiro Namikawa
Honoraria - Bristol-Myers Squibb Japan; Eisai; MSD; Novartis; Ono Pharmaceutical; Pharma International; Takara Bio; Toray Industries
Consulting or Advisory Role - Bristol-Myers Squibb Japan; MSD; Novartis; Ono Pharmaceutical
 
Koji Yoshino
Honoraria - Bristol-Myers Squibb Japan; Novartis; Ono Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis; Ono Pharmaceutical
 
Shusuke Yoshikawa
No Relationships to Disclose
 
Hiroshi Uchi
Honoraria - Bristol-Myers Squibb Japan; MSD; Novartis; Ono Pharmaceutical
 
Katsunobu Goto
No Relationships to Disclose
 
Yoshiyuki Nakamura
Honoraria - Ono Pharmaceutical
 
Satoshi Fukushima
No Relationships to Disclose
 
Yukiko Kiniwa
No Relationships to Disclose
 
Tatsuya Takenouchi
Honoraria - Bristol-Myers Squibb Japan; MSD; Novartis; Ono Pharmaceutical
 
Hisashi Uhara
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Maruho; MSD; Novartis; Ono Pharmaceutical; Pola Pharma
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; MSD; Novartis; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Janssen; Kyowa Hakko Kirin; Mitsubishi Tanabe Pharma; MSD; Novartis; Ono Pharmaceutical; Pola Pharma
Research Funding - Abbvie (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kaken Pharmaceutical (Inst); Kyowa Hakko Kirin (Inst); Maruho (Inst); Mitsubishi Tanabe Pharma (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); Nihonkayaku (Inst); Ono Pharmaceutical (Inst); Pola Pharma (Inst); Taiho Pharmaceutical (Inst); Torii Pharmaceutical (Inst); Tsumura & Co. (Inst)
 
Toru Kawai
No Relationships to Disclose
 
Naohito Hatta
No Relationships to Disclose
 
Takeru Funakoshi
Honoraria - Bristol-Myers Squibb Japan; Minophagen Pharmaceuticals; MSD; Novartis; Ono Pharmaceutical
Research Funding - MSD (Inst); Ono Pharmaceutical (Inst); Zenyaku Kogyo (Inst)
 
Yukiko Teramoto
Honoraria - Bristol-Myers Squibb Japan; Maruho; Ono Pharmaceutical
 
Atsushi Otsuka
Honoraria - Bristol-Myers Squibb Japan; Ono Pharmaceutical
Research Funding - Bristol-Myers Squibb Japan; Ono Pharmaceutical
 
Haruki Doi
No Relationships to Disclose
 
Dai Ogata
No Relationships to Disclose
 
Shigeto Matsushita
Honoraria - Bristol-Myers Squibb Japan; Kyowa Hakko Kirin; MSD; Ono Pharmaceutical
 
Naoya Yamazaki
Honoraria - Bristol-Myers Squibb Japan; MSD; Novartis; Ono Pharmaceutical
Research Funding - Bristol-Myers Squibb Japan (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Takara Bio (Inst)